ATH-1105 is an orally delivered, positive modulator of the neurotrophic HGF system that is currently in a Phase 1 clinical trial with completion expected by year end 2024 and commencement of dosing of ALS patients expected in 2025
View post:
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
-Capricor to Receive $15 Million Equity Investment at a 20% Premium, as well as $20 Million Upfront Payment upon Signing Definitive Agreement with up to $715 Million in Potential Milestones and a Double-Digit Percentage of Product Revenue-
Read this article:
Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of...
Following the launch of Accumulus Synergy’s innovative cloud-based information exchange platform, CSL joins the nonprofit industry association Following the launch of Accumulus Synergy’s innovative cloud-based information exchange platform, CSL joins the nonprofit industry association
See more here:
CSL Joins Accumulus Synergy to Drive Industry Change
WINTER PARK, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- ADIA Nutrition Inc. (OTC Pink: ADIA) has announced the hiring of a prominent Winter Springs law firm to fortify its intellectual property holdings, specifically for its flagship product line under the "Biolete" brand. This strategic move aims to safeguard ADIA's intellectual property in the rapidly expanding markets for high-protein and mushroom-infused coffee products.
Read the original post:
ADIA Nutrition Stakes Claim in $6.7B Industry with Strategic Trademark Expansion
Allschwil, Switzerland – September 17, 2024
See the original post:
Idorsia continues to further the science of sleep and insomnia with new daridorexant data and analyses published at Sleep Europe 2024
NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a company discovering and developing new offerings in human healthcare and wellness, today announced the closing of its previously announced initial public offering of 1,500,000 shares of its common stock at a public offering price of $3.00 per share. The shares began trading on the NYSE American Market on September 16, 2024, under the ticker symbol “IBO”.
Read more from the original source:
Impact BioMedical Inc. Announces the Closing of its Initial Public Offering
Ad hoc announcement pursuant to Art. 53 LR
NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Fairway Consulting Group (FCG), a leading executive search firm focused on providing outstanding talent solutions for the pharmaceutical, biotechnology, diagnostic, and medical device industries, announced today the appointment of Brennan Clark as Vice President of Executive Search.
Read the rest here:
Fairway Consulting Group Appoints Brennan Clark as Vice President of Executive Search
SAN FRANCISCO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced key leadership appointments to drive its next phase of development and operational success. Blai Coll, M.D., Ph.D., has been promoted to Chief Medical Officer, replacing Mark Bach, M.D., Ph.D. as part of a planned succession, effective September 18. Dr. Coll has served as Vice President of Clinical Development at Structure since 2022, leading the GSBR-1290 program, Structure’s oral small molecule GLP-1 agonist that is planned to enter Phase 2b clinical development for obesity in the fourth quarter of 2024. In addition, Ashley Hall, J.D., has been appointed to the newly created position of Chief Development Officer, and will be responsible for clinical development operations, project management, regulatory affairs and quality assurance.
See original here:
Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall,...
MONTREAL, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced a risk of a temporary supply disruption for EGRIFTA SV® (tesamorelin for injection) in early 2025 caused by an unexpected voluntary shutdown of the Company’s contract manufacturer’s facility following an inspection by the US Food and Drug Administration (FDA), as well as the FDA review timeline to resume distribution of the product.
More:
Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV® in Early 2025